Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
厄洛替尼
Подписчиков: 0, рейтинг: 0
臨床資料 | |
---|---|
商品名 | Tarceva |
AHFS/Drugs.com | Monograph |
MedlinePlus | a605008 |
核准狀況 | |
给药途径 | Oral tablets |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 59% |
血漿蛋白結合率 | 95% |
药物代谢 | Hepatic (mainly CYP3A4, less CYP1A2) |
生物半衰期 | 36.2 hrs (median) |
排泄途徑 | >98% as metabolites, of which >90% via faeces, 9% via urine |
识别信息 | |
| |
CAS号 | 183321-74-6 |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.216.020 |
化学信息 | |
化学式 | C22H23N3O4 |
摩尔质量 | 393.436 g/mol |
3D模型(JSmol) | |
| |
|
厄洛替尼(英語:Erlotinib,商品名:Tarceva,特罗凯)是用于治疗非小细胞肺癌(NSCLC)、胰腺癌等几种癌症的药物,作为一种酪氨酸激酶抑制剂作用于表皮生长因子受体,由罗氏公司生产。
藥物合成
- 第一種合成路徑
- 第二種合成路徑
外部链接
- Official Tarceva website (页面存档备份,存于互联网档案馆)
- Tarceva Discussion Group for Cancer Patients (页面存档备份,存于互联网档案馆)
- Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. August 2004, 305 (5687): 1163–7. PMID 15284455. doi:10.1126/science.1101637. .
- Genzyme "Genzyme Launches Exclusive Lung Cancer Test" Press Release September 27, 2005
- "Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer (页面存档备份,存于互联网档案馆), Journal of Clinical Oncology, August 15, 2004.
- October 2003 issue of Lung Cancer Frontiers on rash/effectiveness correlation
- FAQ: I started an EGFR inhibitor two weeks ago but haven’t developed a rash. Does this mean it’s not working?, Dr. Howard L. (Jack) West, M.D., GRACE(页面存档备份,存于互联网档案馆), February 21, 2011 (directed toward the layperson).
- http://www.cancer.gov/clinicaltrials/results/lung-and-erlotinib0604l
- https://web.archive.org/web/20081012081613/http://www.roche.com/med-cor-2007-10-22
- https://web.archive.org/web/20110726060413/http://www.roche.com/med-cor-2009-05-30b
- https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#27apr09
- https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#20mar08
|